Search Results

On May 10, 2024, the BGI-Heilongjiang Omics Health Axis Intelligent Laboratory was inaugurated in Harbin, Heilongjiang province, China, marking a significant advance in the province’s efforts to address public health challenges.

BridGene Biosciences, Inc. announced that it will present a poster, titled “Preclinical characterization of BGI-9004, a covalent TEAD inhibitor with exceptional anti-cancer activity and combination potential,” at the American Association for Cancer Research (AACR) Annual Meeting 2023 on April 18 in Orlando.

BGI Australia’s lab has achieved accreditation from the National Association of Testing Authorities to perform clinical Whole Exome Sequencing in Australia, paving the way for the global life sciences company to provide clinical sequencing services for identifying possible disease-causing genetic changes.

The formal launch of the BGI/Natera Signatera Assay is the next step towards achieving global access to personalized ctDNA testing

In a breakthrough that could lead to scientific advancement in the treatment of human diseases, researchers from BGI-Research, together with scientific research teams from China, Germany, Italy, Singapore, Spain, Sweden and the UK, published the world’s first non-human primate whole-body cell transcriptomic atlas in the scientific journal Nature.

Illumina, Inc. (NASDAQ: ILMN) today announced that the High Court of Justice, Chancery Division, Patents Court, issued a judgment in its favor in the patent infringement suit filed against the BGI Companies, MGI Tech Co. Ltd; Latvia MGI SIA; MGI International Sales Co., Ltd; and BGI Complete Genomics Hong Kong Co., Ltd. The Court found that four of the five asserted patents were valid and infringed by BGI. The Court ruled

Champions Oncology announced today that they have entered into a strategic partnership with BGI Americas.

Illumina, Inc. announced that it has filed a patent infringement suit relating to BGI’s “CoolMPS” sequencing products.

BGI Genomics announced today that its subsidiary BGI Americas Corporation has received authorization under Interim Order from Health Canada to supply its Real-Time Fluorescent RT-PCR Kit for Detecting SARS-CoV-2 in the Canadian market.

Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed three additional patent infringement suits relating to BGI’s sequencing products, including the BGISeq-500, MGISeq-2000, and related chemistry reagents.